Drug class
Orotate phosphoribosyltransferase (OPRT) inhibitor; fluoropyrimidine-modulating component
Mechanism of action
Oteracil potassium preferentially localises in gastrointestinal tissues and inhibits orotate phosphoribosyltransferase, reducing conversion of 5-fluorouracil to active metabolites in the gut and thereby reducing gastrointestinal toxicity when used in the tegafur/gimeracil/oteracil (S-1) combination.
General use cases
- Used only as a component of the fixed-dose tegafur/gimeracil/oteracil combination (S-1/Teysuno) for selected solid tumours; oteracil alone is not a stand-alone antineoplastic treatment.
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
